Latest Carbamates Stories

-- TMC310911 is Third Product in Growing Ascletis Pipeline of Infectious Disease and Cancer Therapeutics -- HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/ -- Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in...

EAST SETAUKET, N.Y., April 25, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667. Dr....

WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH). Both CTEPH and PAH are...

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com New York, NY (PRWEB) March 12, 2013 The drug safety advocates at DrugRisk.com are alerting those patients taking the blood thinner Pradaxa of new information on the site showing the manufacturer, Boehringer Ingelheim, is testing an antidote for internal bleeding, as the number of bleeding injury claims has risen substantially...

Multi-site study, led by a Miriam Hospital researcher, could change treatment strategy for these patients A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression – the primary goal of HIV therapy – without incorporating the traditional class of HIV medications into their treatment regimen. Karen Tashima, M.D., director of the HIV Clinical Trials Program at The Miriam Hospital, served as study chair. The AIDS Clinical Trials Group (ACTG)...

Interim Phase 3 STARTVerso(TM) 4 analysis in co-infected patients showed 80% protocol-defined early treatment success* RIDGEFIELD, Conn., March 4, 2013 /PRNewswire/ -- Today Boehringer Ingelheim Pharmaceuticals, Inc. announced the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso(TM). These results, from the Phase 3 trial STARTVerso(TM) 4, were presented today at the 20(th) annual Conference on...

ROCKVILLE, Md., Feb. 22, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its flupirtine sublicensee, Meda AB (Meda), has received a green light from the Food and Drug Administration (FDA) to conduct a Phase II proof of concept study for the treatment of fibromyalgia as reported in Meda's 2012 year-end report. Meda has announced that the randomized,...

WAYNE, N.J., Feb. 11, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for riociguat, an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. "Bayer is submitting an NDA for riociguat for the treatment...

CORK, Ireland, January 16, 2013 /PRNewswire/ -- In the news release, "European Commission Approves PREZISTA® (darunavir) 800 mg Tablet Once a Day Reducing the Number of Pills Taken by People Living With HIV" issued on 16 Jan 2013 08:00 GMT, by Janssen R&D Ireland over PR Newswire, please be advised that the first note following paragraph three has been corrected to read "i. ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1...

CORK, Ireland, January 16, 2013 /PRNewswire/ -- Janssen R&D Ireland announced today that the European Commission (EC) has approved a new PREZISTA(R) (darunavir) 800mg tablet allowing people living with HIV to take one darunavir tablet once a day. Darunavir is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced and treatment-naive patients with no darunavir resistance-associated...